Welcome to the new Gustave Roussy website
A new website designed to offer you a simpler, clearer, and more intuitive experience. Patients, caregivers, healthcare professionals, and donors: find information, news, and services more easily.
From Hematopoietic Stem Cells to Megakaryocytes
- Thematic(s)
- Cell Dynamics, Onco-hematology, Innovative Therapies
- Manager(s)
- Isabelle Plo, Hana Raslova
- Institutional connection
-
Gustave Roussy, Inserm, Paris-Saclay University
Summary
Themes, Objectives, and Challenges
Our team is studying megakaryopoiesis—the process of platelet production—both in normal and pathological contexts related to myeloproliferative neoplasms (MPNs) and hereditary thrombocytopenias (HTs). Our main objectives are: 1) to understand the initiation of MPNs by determining the age of onset of mutations and the dynamics of mutated CSH; 2) to study normal and pathological megakaryopoiesis by focusing on the pathophysiology of HT, MPDs (at the stages of myeloproliferation and myelofibrosis), and acute megakaryoblastic leukemia; 3) to study the mechanisms of transformation into acute myeloid leukemias (AMLs) secondary to NMPs, hereditary factors (neutropenia, thrombocytopenia, Trisomy 21, 14q32 duplication), or to chemotherapies used in solid tumors; 4) develop innovative selective therapies for MPNs and AMLs, as well as blood transfusion products (platelets produced from iPSCs).
Results, Prospects, and Scientific, Clinical, and Societal Impacts
Our work has helped elucidate the timing of the emergence of JAK2V617F and mutated CALR mutations, their effects on hematopoietic stem cells, and the role of genetic factors in the development of NMPs. It has also helped elucidate the mechanisms by which pathological megakaryocytes induce myelofibrosis and TH. Furthermore, our research has led to a better understanding of leukemic transformation associated with TP53 mutations, trisomy 21, and certain TH. Finally, promising advances have been made in the development of innovative therapeutic approaches, including selective therapies for NMPs and platelet production technologies for clinical use. Our research has significant scientific impact, opens up new therapeutic avenues, and improves the clinical management of hematologic diseases.
Team members
-
Isabelle PLO - Unit Director
Research Director and Equivalents, Inserm
RASLOVA Hana - Team Leader
Research Director and Equivalents, Inserm
Iléana ANTONY-DEBRE
Research Associate and Equivalents, Inserm
ARKOUN Brahim
Research Associate and Equivalents, Inserm
BALAYN Nathalie
Engineering Assistant or equivalent, Inserm
BEL HAJ YAHIA Syrine
Ph.D. Candidate, MENRT
Christine BELLANNE-CHANTELOT
University Lecturer and Hospital Practitioner, Sorbonne University
BORDERON Laetitia
Ph.D. candidate, MENRT
BRUNO, Margherita
Ph.D. Candidate, Paris-Saclay University
Charlotte CHAMBRION
Research Engineer or equivalent, Inovarion
DEBILI Najet
Emeritus Research Director, CNRS
Hélène DUPARC
Research Engineer or equivalent, Inserm, ANR
Léa DURIX
Research Engineer or equivalent, Gustave Roussy, Industry
Salomeh El-Choufani
Ph.D. student, Ligue
Maxime Evrard
Research Technician or equivalent, Gustave Roussy, Industry
FOUQUET Guillemette
University Lecturer—Hospital Practitioner, Paris-Saclay University
GUIGNARD Rose
Ph.D. Candidate, MENRT
LEGROS Laurence
University Lecturer and Hospital Practitioner, Paris-Saclay University
Cécilia MARIN OYARZUN
Postdoctoral Researcher, Gustave Roussy, Industry
Caroline MARTY
Researcher and Equivalents, Inserm
Christophe MARZAC
Hospital Physician, Gustave Roussy
Jean-Baptiste Micol
Hospital Physician, Gustave Roussy
MINO Jhon
Ph.D. candidate, MENRT
PASQUIER Florence
Hospital Physician, Gustave Roussy
Elodie ROSA
Design Engineer or equivalent, Gustave Roussy, Industry
Merwan SADDAR
Ph.D. Candidate, MENRT
THORINIUS Dylan
Research Technician or equivalent, Gustave Roussy, Industry
VAINCHENKER William
Emeritus Research Director, Inserm
Laetitia Vuillemin
Ph.D. Candidate, MENRT
Key publications
Other scientific productions
Contacts
- Phone
- 01.42.11.46.71
